Transfusion use in patients with rare blood cancer (myelodysplastic syndromes)

Transfusion use in patients with myelodysplastic syndromes (MDS): a nationwide, retrospective cohort study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN38059137

Enrollment

3000

Registered

2020-01-24

Start date

2008-01-01

Completion date

Unknown

Last updated

2021-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic syndromes Cancer Myelodysplastic syndromes

Interventions

The study will include all adult patients with a confirmed histopathological diagnosis of MDS in the time period from 2010-2017, living in Sweden. In these patients, researchers will use nationwide re

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with a confirmed histopathological diagnosis of MDS in the time period from 2008-2017, living in Sweden

Exclusion criteria

Exclusion criteria: Reseachers will restrict the analyses to patients with known WHO-subgroup and IPSS/IPSS-R risk group respectively

Design outcomes

Primary

Measure	Time frame
Total transfusion cost, incorporating both direct and indirect costs, related to blood transfusions measured using patient records	—

Secondary

Measure	Time frame
Measured using patient records: 1. Total direct cost for transfusion therapy 2. Total indirect for transfusion therapy 3. Total number of blood transfusions, overall, and divded by component type	—

Countries

Sweden

Contacts

Public ContactGustaf Edgren

gustaf.edgren@ki.se+46 708188662

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026